Paragon Care Limited (PGC) AI Stock Analysis

• Market Cap: AU$314.51M
• Dividend Yield: N/A
• Average Volume (3M): 501.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: 21.68%
• EPS Growth: 37.78%
• Country: AU
• Employees: 400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): -1.29
• Shares Outstanding: 1,655,305,400
• 10 Day Avg. Volume: 605,379
• 30 Day Avg. Volume: 501,285
• PEG Ratio: 0.78
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.17
• P/FCF Ratio: -26.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.32
• Price Target Upside: 65.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.02
• Revenue Forecast (FY): AU$3.67B

• Rating: 47 Neutral
• Price Target: AU$0.18 ▼(-6.84% Downside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is held down primarily by weak financial performance (revenue contraction, thin profitability, and negative operating/free cash flow) and bearish technicals (price below key moving averages and negative MACD). Valuation contributes only modestly because a negative P/E reduces interpretability and no dividend yield is available.

Positive Factors

Stable healthcare distribution model

Distribution plus installation, servicing and consumables creates recurring revenue streams and multi-year customer relationships. That business mix supports stable demand and aftermarket spend, providing durable revenue anchors and service-driven margin opportunities even amid cyclical pressure.

Manageable leverage

A moderate debt-to-equity ratio and a reasonable equity ratio indicate the company is not overlevered, reducing near-term refinancing risk. Combined with a modest ROE, this balance sheet gives flexibility to fund operations or restructuring without immediate solvency pressure.

Improving operating margins

Incremental gains in EBIT/EBITDA margins suggest management has been executing efficiency measures. If sustained, these improvements can enhance cash generation and partly offset revenue headwinds, strengthening operating resilience over the coming quarters.

Negative Factors

Sharp revenue decline

A large drop in revenue materially reduces scale and operating leverage, pressuring gross profit and the ability to cover fixed costs. Prolonged top-line contraction risks supplier terms, investment deferral, and erosion of customer relationships, harming long-term competitiveness.

Thin profitability margins

Very low gross and net margins leave minimal buffer for input cost increases or pricing pressure. In a distribution business, thin margins constrain reinvestment, limit scale economies, and raise vulnerability to contract losses or adverse supplier dynamics over the medium term.

Negative operating cash flow

Persistent negative operating cash flow indicates difficulty converting reported profits into usable cash, increasing reliance on external funding. That hampers working capital management, service/maintenance operations, and capital expenditure plans, and raises financing and execution risk.

Paragon Care Limited Business Overview & Revenue Model

Company Description

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.

How the Company Makes Money

Paragon Care generates revenue primarily through the sale of medical equipment and consumables to hospitals, healthcare facilities, and aging care services. The company's revenue model is based on direct sales, distribution agreements, and service contracts. Key revenue streams include the sale of surgical instruments, diagnostic devices, and rehabilitation products. Additionally, PGC benefits from significant partnerships with leading global manufacturers, allowing them to offer a wide range of high-quality products. The company also engages in value-added services, such as equipment maintenance and training, contributing further to its earnings.

Paragon Care Limited Financial Statement Overview

Summary

Weak financial performance driven by a sharp revenue decline (-22.46%), thin gross margin (8.97%) and net margin (0.57%), and notable cash flow strain with negative operating and free cash flow. Balance sheet leverage is manageable (debt-to-equity 0.93), but overall fundamentals remain pressured.

Income Statement

Paragon Care Limited has experienced a significant decline in revenue growth, with a negative growth rate of -22.46% in the most recent year. The gross profit margin is relatively low at 8.97%, indicating limited profitability from core operations. The net profit margin is also low at 0.57%, reflecting challenges in converting revenue into profit. However, there is a slight improvement in EBIT and EBITDA margins compared to previous years, suggesting some operational efficiency gains.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.93, indicating a balanced approach to leveraging. Return on equity is modest at 6.45%, showing some ability to generate returns for shareholders. The equity ratio stands at 25.84%, suggesting a reasonable proportion of assets financed by equity. Overall, the balance sheet reflects moderate financial stability with manageable leverage.

Cash Flow

Paragon Care Limited faces challenges in cash flow management, with negative operating cash flow and free cash flow in the latest period. The free cash flow growth rate is high at 687.12%, but this is from a negative base, indicating volatility. The operating cash flow to net income ratio is negative, highlighting difficulties in converting accounting profits into cash. The free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net income.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	3.67B	3.61B	2.97B	307.63M	237.62M	235.84M
Gross Profit	243.16M	324.00M	176.07M	51.68M	36.58M	33.41M
EBITDA	41.04M	89.81M	43.18M	37.07M	23.96M	26.54M
Net Income	-13.93M	20.57M	8.38M	12.80M	6.63M	8.28M
Balance Sheet
Total Assets	1.31B	1.23B	1.13B	448.52M	438.44M	291.92M
Cash, Cash Equivalents and Short-Term Investments	30.86M	21.90M	19.94M	970.00K	46.20M	33.20M
Total Debt	464.29M	296.52M	251.83M	122.14M	131.26M	113.01M
Total Liabilities	1.00B	915.04M	838.97M	196.56M	196.31M	170.40M
Stockholders Equity	304.50M	319.00M	291.92M	18.88M	235.82M	121.52M
Cash Flow
Free Cash Flow	-13.40M	-23.04M	25.14M	-3.30M	14.42M	22.18M
Operating Cash Flow	2.61M	-11.35M	44.45M	17.75M	19.03M	27.46M
Investing Cash Flow	-46.98M	-16.64M	-19.52M	-31.75M	7.07M	-18.80M
Financing Cash Flow	58.05M	28.65M	-5.95M	-10.00M	-11.93M	32.00K

Paragon Care Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.22, and below the 200-day MA of 0.31, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.98 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PGC.

Paragon Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	59 Neutral	AU$432.39M	16.69	18.59%	4.60%	6.73%	37.16%
SIG	53 Neutral	AU$32.61B	56.13	―	0.44%	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PGC	47 Neutral	AU$314.51M	-22.62	6.74%	―	21.68%	37.78%
HLS	46 Neutral	AU$497.40M	-0.91	-67.21%	―	-23.02%	33.11%
BOT	44 Neutral	AU$124.21M	-1.20	-90.93%	―	456.50%	-457.14%
MYX	43 Neutral	AU$204.74M	-2.46	-21.13%	―	5.07%	46.14%

Paragon Care Limited Corporate Events

Paragon Care outlines FY26 half-year update with strong disclaimers

Paragon Care Limited has released an investor presentation outlining its FY26 half-year results, providing shareholders with a high-level update on current activities and financial performance. The document emphasises that the material is informational rather than advisory, and cautions investors to consider their own objectives and seek professional guidance when making decisions about Paragon Care shares.

The company also underscores the presence of forward-looking statements that are subject to significant risks and uncertainties, and disclaims any assurance that projected outcomes will be achieved. Management highlights that no warranty is given as to the completeness or accuracy of the data and explicitly limits liability, reinforcing that the presentation should not be taken as a forecast or recommendation for investment decisions.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Highlights Transformation in FY26 Half-Year Report

Paragon Care Limited has released its FY26 half-year report, highlighting its evolution into a leading diversified healthcare provider across the Asia-Pacific region. The company underscores its strategic transformation following the 2024 merger with Clifford Hallam and reiterates its role in making healthcare simpler, smarter and more accessible throughout its markets.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care formalises leadership transition as CEO Carmen Riley becomes Managing Director

Paragon Care has elevated Chief Executive Officer Carmen Riley to the dual role of CEO and Managing Director from 1 March 2026, formalising the next step in a succession plan first outlined in mid-2025. Riley, who has more than 15 years’ experience across Paragon Care and Clifford Hallam Healthcare, is credited with driving operational improvements, integration progress and strategic strengthening as the company prepares for its next growth phase.

Outgoing Managing Director David Collins will move to the role of Executive Director, where he will continue to focus on corporate development, M&A opportunities and completion of key integration initiatives. The leadership reshuffle, backed by the board, is designed to maintain continuity while positioning Paragon Care to accelerate growth in its healthcare markets, underpinned by a detailed employment package for Riley that includes fixed and incentive-based remuneration and defined notice and restraint terms.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Sets Date for 1H FY26 Results and Investor Call

Paragon Care Limited, an Australian-listed healthcare provider, offers a broad range of medical equipment, devices, consumables, pharmaceuticals, complementary medicines, and nutritional supplies. The company also produces blood bank diagnostic reagents, with a geographic focus spanning Australia, New Zealand, and Asia.

Paragon Care will release its half-year FY26 financial results and an accompanying investor presentation to the ASX on 25 February 2026. Following the release, CEO Carmen Riley and CFO Brendon Pentland will host a webcast and conference call with a Q&A session, underscoring the company’s engagement with investors and transparency around its financial performance.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care to Exit Low-Margin Ramsay Pharmacy Contract, Focus on Higher-Value Growth

Paragon Care will cease acting as the primary wholesaler to Ramsay Healthcare’s retail and hospital pharmacy operations from 1 February 2026 after its re-tender bid was undercut by a lower-priced competitor, a contract that added about A$230 million to FY25 revenue but less than 2% to gross margin. Management expects the exit to have an immaterial impact on FY26 earnings as it strips out associated supply chain costs, while the release of roughly A$4.5 million in working capital will be used to pay down debt, reinforcing a strategic focus on higher-margin business, strong underlying healthcare demand and a reported A$1.9 billion in unaudited half-year group revenue.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Director David Collins Increases Indirect Shareholding

Paragon Care Limited has disclosed a change in director David Collins’ indirect interest in the company, with Collins acquiring an additional 2,000,000 ordinary shares via an on‑market trade on 30 December 2025 at $0.2192 per share. The purchase, made through the Collins Millar Family account where Collins is a discretionary beneficiary, lifts his indirect holding to 477,507,317 ordinary shares, signalling a further alignment of the director’s financial interests with those of shareholders and underscoring confidence in the company’s prospects.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Corrects Administrative Error in Director Interest Notices

Paragon Care Limited has corrected three previously lodged Appendix 3Y Change of Director’s Interest Notices after identifying an administrative error in how certain director share transactions were described. The company stated that trades reported on 23 and 24 December 2025 were incorrectly recorded as on‑market transactions and have now been reclassified as off‑market trades, with no other alterations to the original disclosures, signalling that the underlying holdings data remains unchanged for investors and regulators.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Director John Walstab Increases Shareholding via On‑Market Purchase

Paragon Care Limited has disclosed a change in the shareholding of director John Walstab, who holds both direct and indirect interests in the company’s fully paid ordinary shares. The filing shows that Walstab acquired 1,000,000 Paragon Care shares via an on-market trade at $0.18 per share on 19 December 2025, increasing his total holding to 145,591,185 shares, a move that modestly strengthens insider ownership and may be interpreted by investors as a signal of confidence in the company’s outlook.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Director David Collins Increases Indirect Shareholding

Paragon Care Limited has disclosed a change in the indirect interests of director David Collins, whose holdings are associated with the Collins Millar Family account. Collins increased his indirect stake in the company by acquiring 3 million ordinary shares in an on-market trade at $0.1804 per share on 19 December 2025, lifting his total indirect holding from 472.5 million to 475.5 million shares. The company confirmed there were no related changes in contracts and that the transaction did not occur during a closed trading period, signalling routine portfolio adjustment rather than a compliance event.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Director Carmen Riley Increases Shareholding With On‑Market Purchase

Paragon Care Limited has disclosed a change in director Carmen Riley’s shareholding, as required under ASX listing rules. The transaction shows Riley acquired 2,000,000 ordinary shares in an on‑market trade at $0.18 per share on 22 December 2025, increasing her holding to 2,538,888 ordinary shares while retaining 7,480,252 performance rights; no related contracts or trades during a closed period were involved, indicating a straightforward increase in her equity stake that may be interpreted by investors as a sign of confidence in the company.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Responds to Administrator Appointment for Infinity Pharmacies

Paragon Care Limited has reacted to the appointment of administrators for 54 pharmacies within the Infinity Retail Pharmacy Group, expressing surprise and disappointment over the decision, which came unexpectedly amidst ongoing efforts to implement a payment and debt restructuring plan. The company aims to collaborate with receivers, administrators, and stakeholders to facilitate an orderly sale or recapitalization process, aiming to maximize creditor returns and mitigate impacts for stakeholders within the healthcare industry.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Finalizes Somnotec Group Acquisition

Paragon Care Limited has completed the acquisition of the Somnotec Group, excluding its Thailand business, which awaits a foreign business license. The acquisition strengthens Paragon Care’s presence in the Asia Pacific healthcare market, although the pending Thailand acquisition, contributing 17.5% of Somnotec’s EBITDA, is expected to finalize in 6 to 12 months.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Director Increases Shareholding

Paragon Care Limited announced a change in the director’s interest, with Director Carmen Riley acquiring additional ordinary shares. This transaction, conducted through an on-market trade, increases Riley’s holdings and reflects confidence in the company’s future prospects, potentially impacting stakeholder perceptions positively.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Limited Announces Director’s Interest Change

Paragon Care Limited announced a change in the director’s interest, with Carmen Riley acquiring 3,018,108 Performance Rights, as approved at the company’s Annual General Meeting. This change reflects the company’s ongoing commitment to aligning its leadership’s interests with its strategic goals, potentially impacting its operational focus and stakeholder engagement.

The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Expands Asian Footprint with Haju Medical Acquisition

Paragon Care Limited has announced its acquisition of Haju Medical, a leading provider of medical aesthetic services and technology in Indonesia. This strategic acquisition is expected to enhance Paragon Care’s presence in the Asia Pacific region and complement its existing business operations in Thailand and other emerging markets. The acquisition, valued at A$70 million, is anticipated to be earnings accretive for Paragon Care in FY26 and will be funded through existing working capital facilities. The completion of the acquisition is expected by January 2026, subject to customary conditions.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.